Upgrade to SI Premium - Free Trial

Aclaris Therapeutis (ACRS) PT Lowered to $34 at JMP Securities

October 16, 2018 3:18 AM

JMP Securities analyst Donald Ellis lowered the price target on Aclaris Therapeutis (NASDAQ: ACRS) to $34.00 (from $47.00) while maintaining a Market Outperform rating.

Categories

Analyst PT Change

Next Articles